Skip to main content

Table 5 Treatment effects for all contrast in terms of SF36-PCS along with 95% credible interval and probability that treatment is better than the comparator

From: Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis

Intervention

Comparator

MTX

Abatacept + MTX

aTNF + MTX

Tocilizumab + MTX

MTX

Estimate

0

-4.18

-5.24

-4.58

95% CrI

 

(-6.07, -2.27)

(-6.33, -4.16)

(-5.9, -3.27)

P(better)

 

<1%

<1%

<1%

Abatacept + MTX

Estimate

4.18

0

-1.08

-0.41

95% CrI

(2.27, 6.07)

 

(-3.25, 1.11)

(-2.72, 1.87)

P(better)

>99%

 

17%

36%

aTNF + MTX

Estimate

5.24

1.08

0

0.66

95% CrI

(4.16, 6.33)

(-1.11, 3.25)

 

(-1.04, 2.36)

P(better)

>99%

83%

 

78%

Tocilizumab + MTX

Estimate

4.58

0.41

-0.66

0

95% CrI

(3.27, 5.9)

(-1.87, 2.72)

(-2.36, 1.04)

 

P(better)

>99%

64%

22%

 
  1. P(better) = Probability that treatment (in row) is showing greater efficacy than comparator (in column); CrI = credible interval; aTNF = Anti-tumor necrosis factor.